U.S. and World Newswire : Medical : Drugs and Pharmaceuticals News

---

Eularis Exposes Hidden Barriers to Patient Adherence with New Pharmaceutical Industry Report

Published: Wed, 12 Mar 2008, 13:16:18 EDT

Edited by Debra Tone

Non-Adherence Shown to Significantly Impact Patient Health and Financial Performance of Pharmaceutical Companies

NEW YORK, N.Y. and LONDON, U.K., March 12 (SEND2PRESS NEWSWIRE) -- Costing the global pharmaceutical industry an estimated $30 billion per year and causing an estimated 125,000 deaths per year in the United States, patient non-adherence is a looming issue in the healthcare industry. Eularis has responded to this problem with a new report, available today, titled, "Ensuring Profitable Patient Adherence Programs." This report analyzes the underlying barriers to patient compliance and studies how pharmaceutical companies can implement successful adherence programs that will improve patient care while also increasing profitability.

Written for CEOs, marketing executives and sales executives, this report uncovers that while adherence programs are designed to target the obvious reasons for non-compliance, including lack of insurance coverage, poor doctor-patient communication, preference for alternative therapies or simply forgetting, they are often ineffective. The report suggests that this is because there are barriers in the pharmaceutical companies themselves that may be hindering compliance program success. These barriers include such things as siloed organizational structures, privacy issues, short lifecycle of brand managers and difficulty of measuring return on investment.

"Pharmaceutical companies need to reconsider their approach to solving the patient adherence problem and stop viewing non-compliance as 'the patient's problem,'" commented Dr. Andree K. Bates, author of the report and president of Eularis. "In order to implement successful adherence programs that will improve patient care and increase profitability, companies should take an analytical approach that examines all non-compliance data relating to each brand, including how that brand is managed and what the financial impact of non-compliance on that brand is before designing appropriate interventions."

An estimated 70 percent of patients who begin a pharmaceutical therapy discontinue it within one year, even those with chronic conditions that require ongoing treatment or those taking chemotherapy to prevent cancer recurrence. Given recent press reports of drug safety issues, as well as declining sales, greater competition, weaker pipelines, and increasing pressure to reduce direct-to-consumer (DTC) advertising, pharmaceutical companies can no longer ignore the hidden value available by increasing patient adherence.

The report identifies and provides insight into key elements that affect patient compliance, such as:

* Underlying patient reasons for non-adherence
* How pharmaceutical companies can measure the financial impact of non-compliance
* Program approaches for improving patient adherence
* Tips for better patient-physician communication
* Steps to increase patient adherence

The report also presents case studies that demonstrate how to effectively implement various adherence program approaches for several drug categories.

In closing, Bates said, "Adherence to prescribed medications, particularly for long-term therapies, poses a tremendous challenge to the world's pharmaceutical companies. Investigating brand-specific compliance rates, understanding the larger causative factors for lack of compliance, and developing and implementing programs to increase compliance can help brand managers increase market share and revenues for their brands while significantly improving clinical outcomes for patients."

Bates has gained wide recognition within the international pharmaceutical industry for her expertise in marketing return analysis. In addition to this and other must-have reports for pharmaceutical industry marketers, she has authored many articles in peer-reviewed journals and several chapters in books on pharmaceutical analytics.

To purchase the Eularis report, "Ensuring Profitable Patient Adherence Programs" visit: www.patientadherenceroi.com or for more information about Eularis visit www.eularis.com

About Eularis
Eularis provides sophisticated pharmaceutical analytics that provide data-driven insight into the financial impact of corporate and marketing decisions. Unlike traditional analytics approaches whose reliance on historical or analogue data reduces their accuracy, Eularis' proprietary 94.8 Analytics Process is based on the current market situation. This proven approach helps pharmaceutical marketing teams to quickly plan, measure, validate, and optimize their sales and marketing performance. Eularis offers pre-launch analytics, marketing mix modeling (both professional and consumer), portfolio optimization, sales force effectiveness, managed care analytics, and patient compliance solutions.

Co-headquartered in London and New York City, the company has developed significant experience in the global pharmaceutical market through client engagements with AstraZeneca, GlaxoSmithKline, Merck, Pfizer and many others.

More information about Eularis: www.eularis.com.

All trademarks acknowledged.

 View This Release in Japanese (PDF)

 Send2Press® is the originating wire service for this story.

» Read More Drugs and Pharmaceuticals News
» Other Send2Press Industry News by Category

 

---

Drugs and Pharmaceuticals Epeius Biotechnologies' Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for The Treatment of Osteosarcoma Phase I/II Study of Targeted Gene Delivery In Vivo - Intravenous Infusions of REXIN-G CYNACON / OCuSOFT(R) Announces OCuSOFT(R) Lid Scrub(TM) PLUS Now Available in CVS Pharmacies Targeted Gene Delivery Signals Cancer Vaccination in Vivo TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008) ASCO 2008: Tumor-Targeted Rexin-G Demonstrates Dose-Dependent Anti-Tumor Activity without Toxicity in Metastatic Pancreatic Cancer Eularis to Address Marketing Return at Japanese Pharmaceutical Marketing Excellence Conference Eularis to Address Making the Right Research Decision for ROI Interim Analysis of Phase I/II Study of Rexin-G Confirms Efficacy with No Dose Limiting Toxicity in Metastatic Pancreatic Cancer Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R) Mark Whitacre, Ph.D. Promoted at Cypress Systems, Inc. and a Warner Bros. Movie to be Filmed About Him Epeius Biotechnologies Awarded U.S. Patent for Targeted Injectable Gene Delivery In Vivo Eularis Exposes Hidden Barriers to Patient Adherence with New Pharmaceutical Industry Report MEDIA ALERT: Eularis to Address Marketing Return at Measuring Marketing ROI in Pharma Conference in London Losing Weight But Still Have Belly Bulge? Myo-Med, Tom Brady and STG Media Corp. Team Up to Jump Start Myo-Med's 2008 Advertising Campaign Recent Studies Suggest Popular 'Diet Pill' Reduces Acne Breakouts deverus, Inc. Partners with eScreen Inc. to Offer First and Only Instrumented Instant Drug Testing Device to Clients Epeius Biotechnologies Applauds the Belated Scholarship of Their Academic Contemporaries in 2007, As Targeted Gene Therapy Comes of Age in Clinical Medicine ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G, a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer New Report Examines Pharmaceutical Sales Force Effectiveness FDA Approves the Opening of a Phase II Registration Protocol Using REXIN-G(R) for Osteosarcoma in California U.S.A. OCuSOFT Refutes Comparison Time-Kill Study Released by Advanced Vision Research Ophthalmic Research and Development Company Launches Adjunctive Eyelid Therapy and Hygiene Product U.S. Pharmaceuticals Spend $8 Billion Annually in R&D Conducted Overseas - New Clintelligence(R) Alignment Module Advances Global Management » View All News Channels » Press Release Services » Send2Press Home Page

U.S. and World Newswire Millions of Americans Face $100,000-Plus Annual Hit for College and Long-Term-Care Combo Podclass Announced as Recipient of fbFund for Application Built on Facebook(R) Platform Renewable Energy Division Created at S+H Construction New Devices Move Internet Videos Off PCs and Into Homes, Changing TV Forever, says Insight Research Iglesias Nights - An Evening of Salsa Dancing and Latin Culture in Los Angeles - Giving Back to the Community with a Message of Hope and Success Power Sports Factory, Inc. Engages American Financial Strategies to Promote Its Line of High Quality, Fuel Efficient, Premium Motorbikes Get Green with Leader Phone(R) Web 2.0 Audio Conferencing STG Media Corp and STG Interactive Help Launch Innovative Electro-Magnetic Pain Product in Canada Mentoring Success Group Launches 'We Mentor Success' Events for Small Businesses Paramito Global Holdings Announces Investment Activities Telecom Training For Government Will Stretch Tax Dollars CareTools Announces iChart Available on Apple App Store ClusterSeven Releases New Version of its Spreadsheet Monitoring and Control Software WhiteFlash.com Reaches Big 'O' Status in July S+H Construction Announces Renewable Energy Division Red Canyon Pictures Announce a Sneak Peek of Film 'Red Canyon' at HBO Presents: NYLIFF World's Greatest Endurance Man Attempts Record Breaking Feats in New York City LTC Financial Partners Named as Long Term Care Insurance Source by Kiplinger's 2nd Year in a Row Paradigm Multimedia Technology Changes the Rules for Health Care TV Systems Online Event Registration Equals Success for Event Marketing PreViser Corporation Appoints Director of Medical Technology to Expand Further into Medicine MMC Creates Unique Opportunities for Advertisers to Reach Horror Enthusiast The National Urban and Community Forestry Advisory Council (NUCFAC) Hosts Public Forum on A Comprehensive Look at Tropical Forestry Popular Orthopedics Medical Handbook Now Available in Portuguese E-Cap from JAF Industries Can Save Homeowners Thousands of Dollars on a $10 Purchase » View All News Channels » Press Release Services » Send2Press Home Page